Sarepta Therapeutics Announces First Quarter 2021 Financial Results and Recent Corporate Developments
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Sarepta Therapeutics (SRPT) Tops Q1 EPS by 23c, Revenues Beat
May 5, 2021 4:39 PM EDTSarepta Therapeutics (NASDAQ: SRPT) reported Q1 EPS of ($1.54), $0.23 better than the analyst estimate of ($1.77). Revenue for the quarter came in at $146.93 million versus the consensus estimate of $143.33 million.
In the first quarter, we obtained FDA approval for and launched our third RNA therapy for Duchenne, AMONDYS 45 (casimersen). The first AMONDYS 45 patient was treated within the first week of approval. Serving the community with EXONDYS 51, VYONDYS 53, and AMONDYS 45, we achieved net product revenue of $124.9 million, a 24%... More
